Abstract: A topical composition comprising a lipoic acid, a carnitine, and a carnosine in a suitable vehicle for topical application and a method for treating skin is provided. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles and loss of elasticity. Preferred components include R-lipoic acid or R-dihydrolipoic acid, acetyl-l-carnitine, and l-carnosine.

Abstract: Disclosed herein is an intradermal pharmaceutical composition for application to the scalp of a person for improving the bodily appearance comprising plurality of growth factors, peptides and nourishing complex in an amount effective to treat or to prevent hair loss by stimulating hair follicles and promoting hair growth, where such hair growth improves the bodily appearance of the said person.

Abstract: Hair treatment agents include selected protein hydrolysates and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines.

Abstract: The present invention relates to hair treatment agents that include a synergistic combination of selected UV filters and selected complexes of acid protein hydrolysates and basic fatty acid amidoamines.

Abstract: Compositions for treating keratinic fibers, in particular human hair, which in addition to the conditioning properties and the gloss and tactile properties of keratinic fibers, in particular human hair, exhibit an improved action over prior art compositions with regard to the removal of dandruff from the keratinic fibers.

Abstract: Hair treatment compositions include a synergistic combination of fragrances and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines.

Abstract: Provided herein are microalgal polysaccharide compositions and. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.

Abstract: Cosmetic preparations based on hydrophobically modified (meth)acrylic acid copolymers and hydrophobically modified polysaccharides are described, together with related methods of use thereof for the temporary shaping of keratin-containing fibers, in particular human hair.

Abstract: A hair cosmetic composition comprising the following components (A) and (B) and having a pH of 6 or less: (A) an oxyalkylene polymer represented by the following general formula (a1): -(AO)n— (a1) wherein A represents an alkylene group having 2 to 6 carbon atoms and n represents a number from 50 to 30,000, provided that n number of AOs consist of at least two alkyleneoxy groups and are arranged through either random polymerization or block polymerization; and (B) a polymer containing a component unit represented by the following general formula (b1) and a component unit represented by the following general formula (b2) in a mass ratio (b1)/(b2) of 50/50 to 100/0: —(CH2CR1COOH)— (b1) —(CH2CR2COOR3)— (b2) wherein R1 and R2 represent H or CH3 and R3 represents a C2-20 hydrocarbon group.

Abstract: The invention relates to single-phase transparent hair-conditioning gels, comprising a cationic polymer, a polyhydroxy compound, and a cationic surfactant and/or an amine in a cosmetically acceptable carrier, to the use of the composition for haircare, and to a method of caring for the hair using the composition and a process for preparing the composition.

Abstract: The present invention relates to compositions for making up and/or caring for the skin and/or the lips, comprising at least one fatty phase comprising:—at least one hydrocarbon-based resin with a number-average molecular weight of less than or equal to 10 000 g/mol,—at least one hydrocarbon-based block polymer,—from 19% to 80% by weight of non volatile phenylated silicone oil(s) having at least a dimethicone part, relative to the total weight of the composition, and—from 1% to 80% by total weight of non volatile hydrocarbonated apolar oil(s), relative to the total weight of the composition.

Abstract: A dental care product comprises an orally acceptable carrier or excipient, and a bacterial resistance copolymer, which comprises a zwitterionic block and a charged anchoring block, wherein the anchoring block binds to tooth surfaces by electrostatic attraction, and the zwitterionic block extends outwardly to reduce the attachment of bacteria to tooth surfaces.

Abstract: The present invention relates to hair care products including Osage Orange in the form of the botanical extract, seed oil, or combinations of the same. The compositions of the invention synergistically react to stabilize the compositions and provide anti-oxidant, moisturizing, and conditioning benefits to hair and the scalp, while cleansing the hair and not removing essential oils. In further embodiments, the compositions of the present invention can be used for healing hair or styling hair, while providing the benefit of moisturizing and providing anti-oxidants. Moreover, embodiments of the invention can be substantially free of harsh chemical preservatives and chemically synthesized anti-oxidants.

Abstract: The invention refers to a natural hair re-coloration and hair growth composition comprising boiled Makroot fruit (Citrus hystrix DC Rutaceae) that when applied returns white or grey hair to its original color and causes newly re-grown hair to return to its original color as well. The composition also stimulates hair growth. It is composed of natural organic ingredients and thus the composition is low cost and easy to prepare and the application of the composition is quite simple.

Abstract: A dermatological composition for inhibiting or treating inflammation and/or aging of skin includes a dermatologically compatible component and cultured cells derived from the Theobroma cacao plant or an extract thereof. The cultured cells including anti-oxidant and/or anti-inflammatory compounds that reduce inflammation and/or aging when delivered to the skin.

Abstract: The present invention relates to cosmetic and skin care compositions comprising magnetosomes. The invention also relates to methods for the treatment of diseases associated with increased proliferation or accumulation of differentiating keratinocytes.

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract: Pharmaceutical compositions, systems and methods suitable for respiratory delivery of a fixed combination of LAMA, LABA, and ICS active agents are described. The pharmaceutical compositions described herein may be formulated for respiratory delivery via a metered dose inhaler (MDI). Also described herein are MDI systems for delivery of a fixed combination of LAMA, LABA, and ICS active agents, as well as methods for preparing and using the compositions and systems described herein.

Abstract: A method for delivering a compound through a biological barrier including applying a force to a plurality of microparticles on a surface of the barrier so that at least some of the microparticles penetrate the biological barrier to facilitate delivery of the compound therethrough.

Abstract: An antimicrobial composition and methods of making the same are disclosed herein. In one aspect of the invention, an antimicrobial composition comprising one or more bioresorbable polymer drug particles and at least one polymer, the polymer drug particle including at least one bioresorbable polymer and at least one antimicrobial agent, wherein the composition is formulated for topical application to a surgical incision site in the subject.

Abstract: The present invention is related to a composition for enhancing topical and transdermal absorption comprising an alkali material having a pH in the range of about 9.0 to 14.0 and a water-soluble substance in an amount of more than 0.5 wt % based on a total weight of the composition. The present invention is also related to a pharmaceutical composition comprising the composition, at least one therapeutically effective amount of a drug or an effective cosmetic ingredient, and a pharmaceutically acceptable carrier. The present invention is also related to a method for enhancing and delivering a drug through a body surface to minimize or eliminate the possibility of skin damage, irritation or sensitization while the above-described composition or the pharmaceutical composition is crossing patient's skin or mucosal tissue.

Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.

Abstract: Products and methods are disclosed for reducing the production of unwanted odors from the pudendum.

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.

Abstract: A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-?-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

Abstract: The invention provides cryopreserved encapsulated cell therapy devices that are capable of delivering biologically active molecules as well as methods of using these devices.

Abstract: An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.

Abstract: The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human ?-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in significant enzyme uptake, significant rh-iduronidase activity in brain and meninges and a decrease of glycosaminoglycan (GAG) storage in cells of MPS I subjects to that of normal subjects. Intrathecal administration proved more effective than intravenous treatment at alleviating MPS I symptoms, indicating it is a useful method of treating lysosomal storage disorders.

Abstract: The present invention is directed to metal supplementation of beverages. More particularly, it is directed to a metal containing complex coacervate core micelle comprising a negatively charged chelating agent, a low molecular weight natural food-grade polymeric cation, and water. It is also directed to a process to produce said metal containing complex coacervate core micelle, and to the use of said metal containing complex coacervate core micelle to supplement beverages with a source of highly bioavailable metal. It is also related to a beverage comprising said metal containing complex coacervate core micelle.

Abstract: A double-layered liposome comprising a first liposome comprising a hydrophobic active ingredient and a first lipid bilayer containing the hydrophobic active ingredient; and a second liposome comprising a second lipid bilayer having an inner space in which the first liposome is located; and a method of using the double-layered liposome.

Abstract: This invention relates to novel pharmaceutical compositions for inhalation comprising separately or together the long acting muscorinic antagonists (LAMAs) in the form of a dry powder in admixture with a pharmaceutically acceptable carrier and its use in the treatment of respiratory condition selected from asthma, chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases.

Abstract: An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol.

Abstract: This cellulose powder has: an average degree of polymerization of 100 to 350; a weight average particle size of over 30 ?m, but less than 250 gm; an apparent specific volume of 2 to less than 15 cm3/g; and a particle size distribution sharpness of 1.5 to 2.9.

Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.

Abstract: The present invention aims to provide a matrix-type solid preparation that has high-level release controllability for suppressing drug release in the upper gastrointestinal tract and accelerating drug release in the lower gastrointestinal tract, and that solves of all the above drawbacks caused by combining a plasticizer. The present invention provides a method for producing a matrix-type pharmaceutical solid preparation that contains: (a) a methacrylic acid-based enteric polymer; (b) a sugar and/or a sugar alcohol, and (c) tolvaptan.

Abstract: Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template.

Abstract: A method of treating at least one of COPD and/or asthma in a subject is provided, wherein an inhalable medicament is administered, in particular a new solid-state form of tiotropium bromide. The medicament can be in the form of solid amorphous particles containing an intimate admixture of tiotropium bromide together with a pharmaceutically acceptable co-solid having a glass transition temperature of at least -50° C., such as a sugar and/or sugar alcohol.

Abstract: Multi-layer solid oral dosage immediate release and extended release compositions and methods for delivering drugs in abnormally high pH environments wherein the extended release layer is formed from a drug resinate of a strong acid ion-exchange resin and a release rate retarding polymer compressed together.

Abstract: The invention provides solid dose forms (e.g. tablets) comprising a compound of Formula I, a compound of Formula II, a compound of Formula III and a salt of Formula IV.

Abstract: The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.

Abstract: The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an individual.

Abstract: The object of the present invention is to provide a tablet manufacturing method and also to provide a tablet such as a carbonated spring bathing liquid in which although an aqueous solution after dissolution of the tablet becomes neutral in pH, neutralization reactions are allowed to take place efficiently and intensively inside the tablet, bubbles of carbon dioxide gas which are small in size as much as possible are continuously generated for a certain period of time, thereby the thus generated carbon dioxide gas is mostly dissolved in water without escaping into the air to increase concentrations of total carbonate components in water, and carbon dioxide gas in contact with the skin is designed to be easily converted to bicarbonate ions due to a pH value of the aqueous solution thereof and, therefore, absorbed through the skin, and this subject is solved by a tablet manufacturing method for conducting compression molding in the presence of an organic acid in a range of 1:10 to 1:3 and polyethylene glycol in

Abstract: The present invention relates to stable oral pharmaceutical compositions comprising solifenacin or a salt thereof prepared by a double compaction process, wherein the amorphous content of solifenacin or a salt thereof in the composition is not less than 80% by weight. It further relates to a method of treating or preventing overactive bladder syndrome by administering said pharmaceutical compositions.

Abstract: A solid formulation of clopidogrel bisulfate and its preparation method are disclosed. The formulation includes clopidogrel bisulfate as active ingredient, colloidal silicon dioxide as anti-adherent/coating and the carriers selected from diluent, binder, glidant, disintegrant and/or lubricant.

Abstract: Drug formulations having reduced abuse potential which contain one or more of (1) a bittering agent, (2) a bright deterrent/indicator dye and (3) fine insoluble particulate matter. The bittering agent and dye are in a form which does not affect proper administration of the drug, but the bittering agent creates a bitter side effect when the dosage form is crushed or chemically extracted and nasally, orally, buccally or sublingually administered and the dye produces a bright color when crushed and contacted. The fine insoluble particulate matter hinders extraction of the drug from the dosage form and, when crushed, can deter intravenous injection because of the presence of the insoluble particles or hinder injection by blocking an intravenous needle. The bright color of the dye, when extracted, also has a psychologically deterrent effect on intravenous abusers.

Abstract: A film-forming composition comprising (a) a cellulose derivative such as HPMC and (b) a urea additive selected from urea, urea derivatives and mixtures thereof; the use of the film-forming composition as a shell material for hard capsules; and films and hard capsules prepared from the film-forming composition.

Abstract: A composition that includes a nanoparticle. The nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH). The shell includes poly L-arginine. The SNACH is ionically or covalently bonded to the poly L-arginine. A method for treating a disorder of a subject includes: administering to the subject a therapeutically effective amount of the composition for treating the disorder. The disorder is a vascular disorder, a complication of the vascular disorder, or a combination thereof.

Abstract: Compositions containing opioid antagonists are disclosed, particularly alvimopan and its active metabolite in solid dosage forms, where the drug is uniformly distributed, achieves the desired bioavailability, and is stable. Methods of preparing and using the compositions containing opioid antagonists are also disclosed. The results are achieved by a combination of processing techniques and component selection.